TW280817B - - Google Patents
Info
- Publication number
- TW280817B TW280817B TW083102586A TW83102586A TW280817B TW 280817 B TW280817 B TW 280817B TW 083102586 A TW083102586 A TW 083102586A TW 83102586 A TW83102586 A TW 83102586A TW 280817 B TW280817 B TW 280817B
- Authority
- TW
- Taiwan
- Prior art keywords
- pct
- formula
- sec
- date
- disclosed
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 abstract 1
- 206010038678 Respiratory depression Diseases 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 230000003931 cognitive performance Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/6533—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/6533—Six-membered rings
- C07F9/65335—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3858493A | 1993-03-26 | 1993-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW280817B true TW280817B (en, 2012) | 1996-07-11 |
Family
ID=21900746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW083102586A TW280817B (en, 2012) | 1993-03-26 | 1994-03-24 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5929236A (en, 2012) |
| EP (1) | EP0690850B1 (en, 2012) |
| JP (1) | JP2778832B2 (en, 2012) |
| AT (1) | ATE160143T1 (en, 2012) |
| AU (1) | AU6408894A (en, 2012) |
| CA (1) | CA2158952C (en, 2012) |
| DE (1) | DE69406779T2 (en, 2012) |
| DK (1) | DK0690850T3 (en, 2012) |
| ES (1) | ES2109683T3 (en, 2012) |
| GR (1) | GR3025950T3 (en, 2012) |
| IL (1) | IL109111A (en, 2012) |
| TW (1) | TW280817B (en, 2012) |
| WO (1) | WO1994022843A1 (en, 2012) |
| ZA (1) | ZA942090B (en, 2012) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0853626A1 (en) * | 1995-09-07 | 1998-07-22 | Novartis AG | Substituted phosphinic compounds and their use as pharmaceuticals |
| AU5859598A (en) * | 1996-12-24 | 1998-07-17 | Novartis Ag | (thio)morpholine-substituted carboxylic and phosphinic acids |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| KR20090064418A (ko) | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | 4-아실아미노피리딘 유도체 포함 조합물 |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4889857A (en) * | 1987-10-12 | 1989-12-26 | Yoshitomi Pharmaceutical Industries, Ltd. | Quinolonecarboxylic acid compounds and pharmaceutical use thereof |
| NZ233503A (en) * | 1989-05-15 | 1991-06-25 | Janssen Pharmaceutica Nv | Substituted (thio)morpholinyl and piperazinyl alkylphenol ethers |
| JPH04270272A (ja) * | 1991-02-25 | 1992-09-25 | Yoshitomi Pharmaceut Ind Ltd | アミノアルキルモルホリン誘導体の製造法 |
-
1994
- 1994-03-23 CA CA002158952A patent/CA2158952C/en not_active Expired - Fee Related
- 1994-03-23 DE DE69406779T patent/DE69406779T2/de not_active Expired - Lifetime
- 1994-03-23 AU AU64088/94A patent/AU6408894A/en not_active Abandoned
- 1994-03-23 JP JP6522103A patent/JP2778832B2/ja not_active Expired - Fee Related
- 1994-03-23 US US08/525,795 patent/US5929236A/en not_active Expired - Fee Related
- 1994-03-23 ES ES94911608T patent/ES2109683T3/es not_active Expired - Lifetime
- 1994-03-23 EP EP94911608A patent/EP0690850B1/en not_active Expired - Lifetime
- 1994-03-23 DK DK94911608.1T patent/DK0690850T3/da active
- 1994-03-23 WO PCT/US1994/002803 patent/WO1994022843A1/en active IP Right Grant
- 1994-03-23 AT AT94911608T patent/ATE160143T1/de not_active IP Right Cessation
- 1994-03-24 TW TW083102586A patent/TW280817B/zh active
- 1994-03-24 ZA ZA942090A patent/ZA942090B/xx unknown
- 1994-03-24 IL IL10911194A patent/IL109111A/en not_active IP Right Cessation
-
1998
- 1998-01-20 GR GR980400120T patent/GR3025950T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU6408894A (en) | 1994-10-24 |
| DE69406779D1 (en) | 1997-12-18 |
| ES2109683T3 (es) | 1998-01-16 |
| GR3025950T3 (en) | 1998-04-30 |
| EP0690850A1 (en) | 1996-01-10 |
| IL109111A0 (en) | 1994-06-24 |
| CA2158952A1 (en) | 1994-10-13 |
| ATE160143T1 (de) | 1997-11-15 |
| ZA942090B (en) | 1994-09-26 |
| CA2158952C (en) | 1999-05-18 |
| WO1994022843A1 (en) | 1994-10-13 |
| JPH08503229A (ja) | 1996-04-09 |
| JP2778832B2 (ja) | 1998-07-23 |
| IL109111A (en) | 1999-07-14 |
| US5929236A (en) | 1999-07-27 |
| DK0690850T3 (da) | 1998-02-09 |
| EP0690850B1 (en) | 1997-11-12 |
| DE69406779T2 (de) | 1998-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY137348A (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same | |
| UA41906C2 (uk) | Спосіб лікування неврологічних порушень, викликаних травмами | |
| BR9609063A (pt) | Dinucleotídeos úteis para o tratamento de doenças pulmonares | |
| TW280817B (en, 2012) | ||
| DE69324466D1 (de) | L-dopa Ester-enthaltende Zusammensetzung | |
| CA2108903A1 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
| RU94044454A (ru) | Ингибитор аутоимунных заболеваний | |
| GEP20002014B (en) | Method for Treatment and/or Prevention of Mania and Bipolar Disorder in Mammals | |
| RU94044356A (ru) | Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с | |
| AU6148696A (en) | Methods of inhibiting pneumocystis carinii pneumonia and compounds useful therefor | |
| DE69522578D1 (de) | Glial neurotropher faktor als nervenschutzmittel | |
| EP0838223A4 (en) | CEREBRAL EDEMA INHIBITOR | |
| HU9303000D0 (en) | Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof | |
| MY104521A (en) | Treatment of depression. | |
| MX9707596A (es) | Benzamidas, el uso de las mismas, composiciones que las contienen, para el tratamiento del transtorno neurodegenerativo, y procedimiento para la preparacion del mismo. | |
| TW244336B (en, 2012) | ||
| ES2138017T3 (es) | Uso de n-(piridinil)-1h-indol-1-aminas para la preparacion de un medicamento para el tratamiento de trastornos obsesivo-compulsivos. | |
| UA66751C2 (en) | Benzamides as medicament for treatment of neurodegenerative state, a method for the preparation thereof (variants), pharnaceutical composition for treatment of neurodegenerative states and a method for treatment | |
| RU94044323A (ru) | Средство ингибирования навязчиво-компульсивных состояний и расстройств потребления | |
| MY108455A (en) | Therapeutic benzazapine compounds. | |
| CA2197869A1 (en) | Therapeutic agent for cartilaginous diseases | |
| MX9704887A (es) | Composiciones farmaceuticas para el tratamiento de trastornos depresivos. | |
| CA2532330A1 (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same |